8.27
-0.04 (-0.48%)
| Previous Close | 8.31 |
| Open | 8.33 |
| Volume | 952,143 |
| Avg. Volume (3M) | 8,749,742 |
| Market Cap | 2,835,198,464 |
| Price / Sales | 106.33 |
| Price / Book | 8.81 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nuvation Bio Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -0.20 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 25,954,439 |
| Laurion Capital Management Lp | 30 Sep 2025 | 9,705,532 |
| Omega Fund Management, Llc | 30 Sep 2025 | 8,831,089 |
| Tang Capital Management Llc | 30 Sep 2025 | 4,200,000 |
| Abrams Capital Management, L.P. | 30 Sep 2025 | 3,811,513 |
| Redmile Group, Llc | 30 Sep 2025 | 3,031,009 |
| Aisling Capital Management Lp | 30 Sep 2025 | 2,960,659 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (B. Riley Securities, 45.11%) | Buy |
| Median | 10.00 (20.92%) | |
| Low | 6.00 (Wedbush, -27.45%) | Buy |
| Average | 9.57 (15.72%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 5.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Dec 2025 | 10.00 (20.92%) | Buy | 7.88 |
| 19 Sep 2025 | 10.00 (20.92%) | Buy | 3.22 | |
| Truist Securities | 24 Nov 2025 | 11.00 (33.01%) | Buy | 7.41 |
| Citizens | 20 Nov 2025 | 10.00 (20.92%) | Buy | 7.01 |
| 04 Nov 2025 | 8.00 (-3.26%) | Buy | 4.83 | |
| B. Riley Securities | 19 Nov 2025 | 12.00 (45.10%) | Buy | 7.15 |
| RBC Capital | 04 Nov 2025 | 8.00 (-3.26%) | Buy | 4.83 |
| Wedbush | 13 Oct 2025 | 6.00 (-27.45%) | Buy | 3.68 |
| 08 Sep 2025 | 6.00 (-27.45%) | Buy | 3.49 | |
| Jefferies | 30 Sep 2025 | 10.00 (20.92%) | Buy | 3.70 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LIU DONGFANG | - | 7.95 | -20,000 | -158,900 |
| Aggregate Net Quantity | -20,000 | |||
| Aggregate Net Value ($) | -158,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 7.95 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIU DONGFANG | Officer | 26 Nov 2025 | Sell (-) | 10,000 | 8.01 | 80,100 |
| LIU DONGFANG | Officer | 26 Nov 2025 | Option execute | 10,000 | - | - |
| LIU DONGFANG | Officer | 25 Nov 2025 | Sell (-) | 10,000 | 7.88 | 78,800 |
| LIU DONGFANG | Officer | 25 Nov 2025 | Option execute | 10,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |